Our team is at the 2026 Alabama Urology Network (AUN) in Point Clear, AL, Oct 30-November 1! Visit the Team @Veracyte, Inc. booth today or tomorrow to learn how Decipher® Prostate & Decipher® Bladder tests support a more personalized approach to care in prostate & bladder cancer.

We’re excited to be at Western Section American Urological Association SurgeWest 2026 (WSAUA) in Lahaina, HI, Oct 25–30! Stop by & meet #TeamVeracyte to learn how Decipher® Prostate & Decipher® Bladder tests can help inform treatment planning in #ProstateCancer & #BladderCancer

Join us at #WSAUA SurgeWest 2026 in Lahaina, HI (Oct. 25-30)! Stop by the @Veracyte booth to learn how #DecipherProstate and #DecipherBladder testing help inform treatment planning. #DecipherTesting #PrecisionMedicine

We’re excited to be at 95th Annual Meeting of the New England section of the AUA, in Hartford, CT, Oct 22–24! Stop by & meet #TeamVeracyte to learn how Decipher® Prostate & Decipher® Bladder tests can help inform treatment planning in #ProstateCancer & #BladderCancer @Veracyte

Join #TeamVeracyte at the NCUA 11th Annual Meeting, Oct. 23-24 in Wilmington, NC! Learn how Decipher® Prostate and Decipher® Bladder provide genomic insights to support treatment planning in #ProstateCancer and #BladderCancer. @Veracyte

We’re at 95th Annual Meeting of The New England AUA, October 22-24 in Hartford, CT! Visit our booth to learn how #DecipherTesting by @Veracyte can support more informed treatment decisions for patients with #ProstateCancer. #PrecisionMedicine #DecipherUrologicCancers

#TeamVeracyte is at the Kentucky Urological Association (KUA) 2026 Annual Meeting, in Lexington, KY, October 17! Stop by to learn how #DecipherTesting can help provide actionable insights for treatment planning for those with #ProstateCancer & #BladderCancer. @Veracyte

We’re here at 100th Annual Meeting of the North Central Section of the AUA, Oct 14-17, 2026! Visit the #TeamVeracyte booth to learn how Decipher® Prostate & Decipher® Bladder testing help support a personalized approach to care for those with prostate & bladder cancer. @Veracyte

Join #TeamVeracyte, at the 1st Annual Jefferson Urology Symposium in King of Prussia, PA! Stop by our booth to learn how Decipher® Prostate & Decipher® Bladder testing provide genomic insights to support care decisions in #ProstateCancer & #BladderCancer. @Veracyte

We're heading to the MedStar Health Advances in Urologic Oncology 2026! Visit the #TeamVeracyte booth in Washington, DC, to learn how Decipher® Prostate & Decipher® Bladder testing can help support clinical decision-making across #ProstateCancer & #BladderCancer care. @Veracyte

We’re here at 100th Annual Meeting of the North Central Section of the AUA, October 14-17, 2026! Visit #TeamVeracyte booth to learn how Decipher® Prostate &Decipher® Bladder testing help support a personalized approach to care for those with prostate and bladdercancer. @Veracyte

Attending the OhioHealth Fall Cancer Conference 2026? We'd love to connect! Stop by the #DecipherTesting by @Veracyte booth October 9-10 in Powell, OH, to meet our team and learn how we can help support more personalized care for patients with #ProstateCancer & #BladderCancer.

We’re at the Connecticut Urology Society Annual Education Meeting! Stop by our booth on October 8 in Southington, CT, to learn how #DecipherTesting by @Veracyte can help provide additional information to support treatment planning in #ProstateCancer & #BladderCancer patients.

We're excited to be at the 2026 Advances in Prostate Cancer Management, October 8-9. Visit our booth to connect with our team & learn how Decipher® Prostate & Decipher® Bladder testing can help support treatment planning in #ProstateCancer & #BladderCancer. @Veracyte

We are proud to announce new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial. The results, which will be presented at the #ASTRO26 Annual Meeting (Abstract #312), demonstrate that the Decipher® Prostate Genomic Classifier can predict which patients are more likely to benefit from adding short-term androgen deprivation therapy (ADT) to dose-escalated radiation, providing Level 1B* prognostic and predictive evidence. | Impact | The findings provide the first evidence that Decipher testing can predict hormone therapy benefit in intermediate-risk prostate cancer, extending its long-established role in assessing the risk of prostate cancer progression to informing treatment selection for patients with intermediate-risk disease. While ADT can reduce the risk of recurrence and distant spread, it can also have metabolic and quality-of-life effects. Because intermediate-risk disease is biologically diverse, clinical variables such as Gleason grade, prostate-specific antigen (PSA) or clinical stage alone may not reveal which patients are most likely to benefit from adding the therapy. The NRG/RTOG 0815 trial analysis helps move #DecipherProstate testing closer to answering  a consequential question in prostate cancer care: Will hormonal therapy make a meaningful difference for this patient? Study author, Angela Jia, M.D., Ph.D. will present the results. | Presentation Details | 📅 Date: Tuesday, September 29 ⏰ Time: 3:55pm – 4:05pm ET 📍 Location: Room 210 *Simon, R. M., Paik, S. & Hayes, D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101, 1446–1452 (2009). doi.org/10.1093/jnci/djp335 | Resources| 📄 Read full press release - investor.veracyte.com/news-r… 🔗 Event information - veracyte.com/company/event/a… #RadOnc #PrecisionOncology #ClinicalTrials #RealWorldData #TeamVeracyte This article contains forward-looking statements. These forward-looking statements involve risks and uncertainties. Please visit our website for more information: veracyte.com/legal/cautionar…

#TeamVeracyte is in Boston September 26–30 for the American Society for Radiation Oncology Annual Meeting (#ASTRO26)! Stop by Booth 1548 to learn how Veracyte is informing clinical decision-making and advancing research in #RadiationOncology through genomic insights in #ProstateCancer. Ask about: 🔹 Decipher® Prostate Genomic Classifier: a test that supports prostate cancer care decision-making, helping clinicians and their patients navigate treatment choices with clarity 🔹 Decipher GRID (Genomic Resource for Intelligent Discovery): a proprietary research-use-only database designed to help advance understanding of urologic cancers at the molecular level | Resources | 🔗 Event details and full presentation schedule - veracyte.com/company/event/a… 📄 Decipher Prostate test - veracyte.com/tests/decipher-… 📄 Decipher GRID data resource - veracyte.com/innovation/deci… #RadOnc #PrecisionOncology #DecipherProstate #DecipherGRID #DecipherUrologicCancers

Attending the 2026 Bladder & Kidney Cancer Academy Meeting in Denver, CO, September 24-26? Visit our booth to learn how #DecipherTesting by @Veracyte, Inc. can help support treatment planning in #ProstateCancer and #BladderCancer. #PrecisionMedicine #DecipherUrologicCancers

We’re at Frontiers in Oncologic Prostate Care and Ablative Local Therapy FOCAL+ 2026, September 24-26 in San Diego, CA! Visit our booth to learn how #DecipherTesting by @Veracyte can support more informed treatment decisions for patients with #ProstateCancer. #PrecisionMedicine

Attending the 2026 Bladder & Kidney Cancer Academy Meeting in Denver, CO, September 24-26? Visit our booth to learn how #DecipherTesting by @Veracyte can help support treatment planning in #ProstateCancer and #BladderCancer. #PrecisionMedicine #DecipherUrologicCancers

We're at the 40th Reed M. Nesbit Urologic Society & Visiting Professor Meeting in Ann Arbor, MI! Visit our booth on September 18 to learn how #DecipherTesting by @Veracyte, Inc. can help support more informed, personalized treatment decisions in #ProstateCancer & #BladderCancer